Article
Hematology
Ye-Xuan Cao, Hui-Wen Zhang, Jing-Lu Jin, Hui-Hui Liu, Yan Zhang, Meng Zhang, Ying Gao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Le-Feng Wang, Run-Lin Gao, Jian-Jun Li
Summary: Elevated levels of Lp(a) are associated with adverse long-term outcomes in patients with prior myocardial infarction, suggesting that measuring Lp(a) may aid in risk assessment and future management of high-risk individuals.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Pharmacology & Pharmacy
Stella Trompet, Iris Postmus, Helen R. Warren, Raymond Noordam, Roelof A. J. Smit, Elizabeth Theusch, Xiaohui Li, Benoit Arsenault, Daniel I. Chasman, Graham A. Hitman, Patricia B. Munroe, Jerome I. Rotter, Bruce M. Psaty, Mark J. Caulfield, Ron M. Krauss, Adrienne L. Cupples, Wouter J. Jukema
Summary: The pharmacogenetic effect of genetic variation on cardiovascular disease risk reduction in response to statin treatment was investigated through a genome-wide association study (GWAS). The results showed that genetic variation did not significantly affect the response of statins on cardiovascular risk reduction. This suggests that genetic testing for predicting the effects of statins on clinical events may not be a useful tool in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Catarina Schiborn, Daniela Weber, Tilman Grune, Ronald Biemann, Susanne Jager, Natascha Neu, Marie Muller von Blumencron, Andreas Fritsche, Cornelia Weikert, Matthias B. Schulze, Clemens Wittenbecher
Summary: This study found differences in the association of retinol and RBP4 (retinol binding protein 4) with cardiovascular diseases and type 2 diabetes. The association was modified by hypertension state, liver function, kidney function, and sex. These findings suggest a complex relationship between retinol, RBP4, and cardiometabolic risk.
CIRCULATION RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Chern-En Chiang, Gregory G. Schwartz, Yedid Elbez, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Andrejs Erglis, Shaun G. Goodman, Emil Hagstrom, J. Wouter Jukema, Evangelos Liberopoulos, Megan Loy, Robert Pordy, Harvey D. White, Tabassome Simon, Philippe Gabriel Steg
Summary: Patients with a previous history of myocardial infarction (MI) after acute coronary syndrome (ACS) are at higher risk for major adverse cardiovascular events (MACE) and death. The PCSK9 inhibitor alirocumab reduces the risk of events in patients with or without previous MI, but the absolute benefit is greater in those with previous MI.
CANADIAN JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Francois Schiele, Nadia Quignot, Artak Khachatryan, Gaelle Gusto, Guillermo Villa, Doreen Kahangire, Jean-Vannak Chauny, Lea Ricci, Gaelle Desamericq
Summary: The study found that high-intensity LLT prescriptions were limited and adherence to LLT was low among patients with a history of myocardial infarction. Higher treatment intensity, adherence, and adherence-adjusted intensity were all associated with a significantly lower risk of major adverse cardiovascular events.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Chandini Raina MacIntyre, Abrar Ahmad Chughtai, Arpita Das, Bayzidur Rahman, Aye M. Moa, Chieh H. Gan, Timothy C. Tan
Summary: The study found a significantly higher rate of laboratory-confirmed influenza among statin users who were not vaccinated. However, there was no significant difference in influenza vaccine effectiveness between statin users and non-users after vaccination. Statin users had a significantly higher risk of influenza, suggesting that they should be vaccinated against influenza.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Multidisciplinary Sciences
Oliver Okoth Achila, Nahom Fessahye, Samuel Tekle Mengistu, Naemi Tesfamariam Habtemikael, Wintana Yebio Werke, Femal Tesfazghi Zemichael, Haben Negash Leghese, Thomas Amanuel Weldegegish, Tsegay Habteab Tekeste, Eyob Yohannes Garoy
Summary: Despite the high and rising burden of arteriosclerotic cardiovascular disease (CVD) in Sub-Saharan Africa, dyslipidemia remains under-diagnosed, under-treated, and under-described. A study conducted in Asmara, Eritrea found a disproportionately high prevalence of dyslipidemias among adults in this population, with low awareness and various associated factors. These findings highlight the importance of early detection, evidence-based interventions, and education in addressing the high burden of atherosclerotic CVDs-related mortality and morbidity in the region.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Thomas R. Berni, Christopher L. Morgan, D. Aled Rees
Summary: The study found that young women with PCOS have an increased risk of developing myocardial infarction, angina, and revascularization. Weight gain and type 2 diabetes were identified as modifiable risk factors that can be intervened upon.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Thomas R. Berni, Christopher L. Morgan, D. Aled Rees
Summary: The study found that young women with PCOS have an increased risk of myocardial infarction, angina, and revascularization, with weight and type 2 diabetes being potentially modifiable risk factors.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Clinical Neurology
Jong Weon Lee, Hunsun Lim, Jong Hun Kim, Hyoung Seop Kim
Summary: The new ACC-AHA guidelines have expanded the number of participants eligible for statin therapy, especially among the elderly. Statin therapy should be considered based on individual risk factors in different population groups.
JOURNAL OF CLINICAL NEUROLOGY
(2021)
Review
Medicine, General & Internal
Jeffrey E. Jones, Kevin S. Tang, Ailin Barseghian, Nathan D. Wong
Summary: Discussions on the exact targets for LDL-C reduction have become more aggressive, especially for high-risk patients with ASCVD. Statin therapy has been proven effective, and recent trials have shown the impact of non-statin therapies as well.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Aniruddh P. Patel, Minxian Wang, James P. Pirruccello, Patrick T. Ellinor, Kenney Ng, Sekar Kathiresan, Amit V. Khera
Summary: This study suggests that there is a linear relationship between Lp(a) concentrations and ASCVD risk, with differences in concentrations across racial subgroups but similar associated risks. High Lp(a) concentrations are also associated with incident ASCVD.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Rafael Diaz, Qian H. Li, Deepak L. Bhatt, Vera A. Bittner, Marie T. Baccara-Dinet, Shaun G. Goodman, J. Wouter Jukema, Takeshi Kimura, Alexander Parkhomenko, Robert Pordy, Zeljko Reiner, Matthew T. Roe, Michael Szarek, Hung-Fat Tse, Harvey D. White, Doron Zahger, Andreas M. Zeiher, Gregory G. Schwartz, Ph Gabriel Steg
Summary: The study investigated the effects of PCSK9 inhibitor alirocumab on major adverse cardiovascular events in patients with acute coronary syndrome under different intensity of background statin treatment. Alirocumab was found to reduce the relative risk of major adverse cardiovascular events, especially in patients not receiving statin therapy.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Multidisciplinary Sciences
Manel Boumegouas, Manjunath Raju, Joseph Gardiner, Neal Hammer, Yehia Saleh, Abdullah Al-Abcha, Apoorv Kalra, George S. Abela
Summary: This study is the first to demonstrate an interaction between pathogenic bacteria and cholesterol crystals (CCs), showing that bacteria dissolve and bind to CCs. This interaction helps to elucidate adhesion of bacteria to sclerotic valves and atherosclerotic plaques, which may contribute to endocarditis and plaque destabilization.
Article
Cardiac & Cardiovascular Systems
Hadrien Beuret, Nadine Hausler, David Nanchen, Marie Mean, Pedro Marques-Vidal, Julien Vaucher
Summary: The study in Switzerland validated the AGLA and ESC algorithms for predicting atherosclerotic cardiovascular disease, with similar accuracy between the two algorithms, but a quarter of patients developing atherosclerotic cardiovascular disease were not identified by preventive algorithms as eligible for statin therapy.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)